Fulcrum Therapeutics, Inc. cotiza a 3.75 USD y tiene una capitalización bursátil de $286M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in pha…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.22 | $-0.25 | $-0.31 |
| Estimado | $-0.11 | $-0.22 | $-0.30 | $-0.30 |
| Sorpresa | — | +0.0% | +16.7% | -3.3% |
| Métrica | FULC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -21.5% | -40.4% | +18.9% |
| ROA | -20.4% | -32.0% | +11.6% |
| Current Ratio | 27.40 | 2.84 | +24.56 |
| Debt / Equity | — | 0.28 | — |